Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 9, 2013, Pages 1489-1498

  Chantzi, Nuiki I ^a,b   Tiniakos, Dina G ^a   Palaiologou, Marina ^a   Goutas, Nikolaos ^c   Filippidis, Theodoros ^d   Vassilaros, Stamatis D ^e   Dhimolea, Eugen ^b   Mitsiou, Dimitra J ^b   Alexis, Muichael N ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INSTITUTE OF BIOLOGY   (Greece)

^c Evgenidio Infirmary   (Greece)

^d Micromedica Histopathology Laboratory   (Greece)

^e Prolipsis Breast Diagnostic Center   (Greece)

Author keywords

Breast cancer prognosis; Estrogen receptor 2; Immunohistochemistry

Indexed keywords

ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 1; ESTROGEN RECEPTOR BETA 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER RECURRENCE; CELL NUCLEUS; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOPLASM; DISEASE COURSE; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA NEGATIVE BREAST CARCINOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRIPLE NEGATIVE BREAST CANCER; UNIVARIATE ANALYSIS;

ADULT; AGED; BREAST NEOPLASMS; CELL NUCLEUS; CYTOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84882608344     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1467-4     Document Type: Article

References (38)

1. Chantzi NI, Meligova AK, Dhimolea E, Petrou CC, Mitsiou DJ, Magafa V, Pechtelidou A, Florentin I, Kitraki E, Cordopatis P, Tiniakos DG, Alexis MN (2011) Insights into ectopic estrogen receptor expression, nucleocytoplasmic distribution and interaction with chromatin obtained with new antibodies to estrogen receptors α and β. Steroids 76:974-985. doi: 10.1016/j.steroids.201105010
2. Dey P, Jonsson P, Hartman J, Williams C, Ström A, Gustafsson JÅ (2012) Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 26:1991-2003. doi: 10.1210/me.20121227
3. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA, Rochefort H (2005) Increased estrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res 11:3170-3174. doi: 10.1158/ 10780432CCR042298 (Pubitemid 40637201)
4. Fujimura T, Takahashi S, Urano T, Ogawa S, Ouchi Y, Kitamura T, Muramatsu M, Inoue S (2001) Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun 289:692-699. http://dx.doi.org/10.1006/bbrc.2001.6038 (Pubitemid 33152289)
5. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A, Ferno M (2007) Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 13:1987-1994. doi: 10.1158/1078-0432.CCR-06-1823 (Pubitemid 46649864)
6. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481 (Pubitemid 29220854)
7. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26:3727-3734. doi: 10.1200/JCO2007142968
8. Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM (2004) ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23:5799-57806. doi: 10.1038/sjonc1207765
9. Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, Lee JS (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23:1724-1736. doi: 10.1038/sjonc1207315 (Pubitemid 38445164)
10. Jensen EV, Cheng G, Palmieri C, Saji S, Mäkelä S, Van Noorden S, Wahlström T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA 98:15197-15202. doi: 10.1073/pnas.211556298 (Pubitemid 34019150)
11. Leung YK, Mak P, Hassan S, Ho SM (2006) Estrogen receptor (ER)-beta isoforms: A key to understanding ER-beta signaling. Proc Natl Acad Sci USA 103:13162-13167. doi: 10.1073/pnas.0605676103 (Pubitemid 44338933)
12. Leung YK, Lam HM, Wu S, Song D, Levin L, Cheng L, Wu CL, Ho SM (2010) Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer 17:675-689. doi: 10.1677/ERC090294
13. Leung YK, Lee MT, Lam HM, Tarapore P, Ho SM (2012) Estrogen receptor-beta and breast cancer: translating biology into clinical practice. Steroids 77:727-737. doi: 10.1016/j.steroids201203008
14. Marotti JD, Collins LC, Hu R, Tamimi RM (2010) Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 23:197-204. doi: 10.1038/ modpathol2009158
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235. doi: 10.1007/s1054901220406 (Pubitemid 44631925)
16. Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE (2007) Expression of ERa and ERb in lobular carcinoma in situ. Histopathology 50:875-888. doi: 10.1111/j.1365-2559.2007.02689.x (Pubitemid 46850064)
17. Miller WR, Anderson TJ, Dixon JM, Saunders PT (2006) Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br J Cancer 94:1333-1338. doi: 10.1038/sj.bjc.6603082
18. Murphy LC, Leygue E (2012) The role of estrogen receptor-β in breast cancer. Semin Reprod Med 30:5-13. doi: 10.1016/j.steroids201203008
19. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57:523-528. doi: 10.1136/jcp2003008599 (Pubitemid 38655949)
20. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nistico C, Fabi A, Buglioni S, Natali PG, Mottolese M (2008) A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: An observational prospective study. Breast Cancer Res 10:R74. doi: 10.1186/bcr2139
21. O'Neill PA, Davies MP, Shaaban AM, Innes H, Torevell A, Sibson DR, Foster CS (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91:1694-1702. doi: 10.1038/sj.bjc.6602183 (Pubitemid 39546143)
22. Palmieri C, Saji S, Sakaguchi H, Cheng G, Sunters A, O'Hare MJ, Warner M, Gustafsson JA, Coombes RC, Lam EW (2004) The expression of oestrogen receptor(ER)-beta and its variant, but not ERalpha, in adult human mammary fibroblasts. Mol Endocrinol 33:35-50. doi: 10.1677/jme00330035 (Pubitemid 39206346)
23. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423-428. doi: 10.1158/00085472CAN032446 (Pubitemid 38114127)
24. Peng B, Lu B, Leygue E, Murphy LC (2003) Putative functional characteristics of human estrogen receptor-beta isoforms. J Mol Endocrinol 30:13-29. doi: 10.1677/jme.0.0300013 (Pubitemid 36305253)
25. Rhodes A, Jasani B, Balaton AJ, Miller KD (2000) Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 53:292-301. doi: 10.1136/jcp534292 (Pubitemid 30180402)
26. Risbridger GP, Davis ID, Birrell SN, Tilley WD (2010) Breast and prostate cancer: more similar than different. Nat Rev Cancer 10:205-212. doi: 10.1038/nrc2795
27. Secreto FJ, Monroe DG, Dutta S, Ingle JN, Spelsberg TC (2007) Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. J Cell Biochem 101:1125-1147. doi: 10.1002/jcb21205 (Pubitemid 47253715)
28. Shaaban AM, Jarvis C, Moore F, West C, Dodson A, Foster CS (2005) Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 29:1593-1599
29. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14:5228-5235. doi: 10.1158/1078-0432CCR074528
30. Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95:616-626. doi: 10.1038/sj.bjc6603295 (Pubitemid 44325902)
31. Skliris GP, Leygue E, Watson PH, Murphy LC (2008) Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109:1-10. doi: 10.1016/j.jsbmb.2007.12.010
32. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004) Estrogen receptor beta inhibits 17 beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 101:1566-1571. doi: 10.1073/pnas.0308319100 (Pubitemid 38236167)
33. Thomas C, Gustafsson JÅ (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597-608. doi: 10.1038/nrc3093
34. Tonetti DA, Rubenstein R, DeLeon M, Zhao H, Pappas SG, Bentrem DJ, Chen B, Constantinou A, Jordan VC (2003) Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 87:47-55. http://dx.doi.org/10.1016/j.jsbmb.2003.07.003 (Pubitemid 37421338)
35. Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17:R245-R262. doi: 10.1677/ERC100136
36. Weitsman GE, Skliris G, Ung K, Peng B, Younes M, Watson PH, Murphy LC (2006) Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat 100:23-31. doi: 10.1007/s1054900692295
37. Younes M, Honma N (2011) Estrogen receptor β. Arch Pathol Lab Med 135:63-66. doi: 10.1043/20100448RAR1
38. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC (2007) Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7:59. doi: 10.1186/14712407759